Patents by Inventor Wouter Korver

Wouter Korver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA
    Publication number: 20170233449
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: March 2, 2017
    Publication date: August 17, 2017
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Conjugated anti-CD38 antibodies
    Patent number: 9676869
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 13, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 9611322
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20160367695
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 22, 2016
    Inventors: David S. Wilson, Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • METHODS AND COMPOSITIONS FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20160245794
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis, and/or treatment response characterization of individuals suffering from systemic lupus erythematosus (SLE) using single cell network profiling.
    Type: Application
    Filed: August 27, 2015
    Publication date: August 25, 2016
    Inventors: Rachael Hawtin, Wouter Korver, Erik Evensen
  • ANTIBODIES TO NTB-A
    Publication number: 20150376273
    Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
    Type: Application
    Filed: March 26, 2015
    Publication date: December 31, 2015
    Inventors: Arie Abo, Wouter Korver
  • CONJUGATED ANTI-CD38 ANTIBODIES
    Publication number: 20150291702
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 15, 2015
    Inventors: Kathleen Ann ELIAS, Gregory LANDES, Shweta SINGH, Wouter KORVER, Andrew Walling DRAKE, Mary HAAK-FRENDSCHO, Gyorgy Pal SNELL, Vinay BHASKAR
  • Conjugated anti-CD38 antibodies
    Patent number: 9102744
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: August 11, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • ANTI-CD38 ANTIBODIES
    Publication number: 20150203587
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: November 21, 2014
    Publication date: July 23, 2015
    Inventors: Katheen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Antibodies to NTB-A
    Patent number: 8993726
    Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: March 31, 2015
    Assignees: Nuvelo, Inc., ARCA BioPharma, Inc.
    Inventors: Arie Abo, Wouter Korver
  • Anti-CD38 antibodies
    Patent number: 8926969
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: January 6, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20140248238
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: April 28, 2014
    Publication date: September 4, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, JR., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • CONJUGATED ANTI-CD38 ANTIBODIES
    Publication number: 20140155584
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: December 30, 2011
    Publication date: June 5, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    Publication number: 20130344514
    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 26, 2013
    Applicant: AMGEN FREMONT INC.
    Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
  • Methods of monitoring a human anti-human antibody response and inhibitors thereof
    Patent number: 8597615
    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 3, 2013
    Assignee: Amgen Fremont Inc.
    Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
  • ANTIBODIES TO NTB-A
    Publication number: 20130273077
    Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.
    Type: Application
    Filed: June 4, 2012
    Publication date: October 17, 2013
    Inventors: Arie Abo, Wouter Korver
  • Antibodies to CLL-1
    Patent number: 8536310
    Abstract: Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: September 17, 2013
    Assignee: Arca Biopharma, Inc.
    Inventors: Arie Abo, Wouter Korver
  • Anti-CD38 antibodies
    Patent number: 8362211
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: January 29, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    Publication number: 20120219976
    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: AMGEN FREMONT INC.
    Inventors: SIRID-AIMÉE KELLERMANN, LARRY L. GREEN, WOUTER KORVER
  • ANTI-CD38 ANTIBODIES
    Publication number: 20120201827
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: December 30, 2011
    Publication date: August 9, 2012
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar